近日,，來(lái)自米利亞姆醫(yī)院的研究者運(yùn)用一種新的綜合分析技術(shù)分析表明，II型糖尿病病人存在20%患血癌的風(fēng)險(xiǎn),，比如非霍奇金淋巴瘤,、白血病和骨髓瘤。這項(xiàng)研究刊登在了國(guó)際著名雜志Blood上,，研究數(shù)據(jù)為糖尿病和特定類型的癌癥之間的聯(lián)系提供了證據(jù),。
研究者Jorge Castillo表示，大多數(shù)人只認(rèn)為心臟疾病,、腎衰竭和糖尿病直接相關(guān),，然而在超過(guò)1900萬(wàn)被診斷患有糖尿病的美國(guó)人中患血癌等風(fēng)險(xiǎn)比例提高了20%。以前的研究表明,，糖尿病和肝癌,、胰腺癌有關(guān)系，很少有研究揭示血癌和糖尿病之間的關(guān)系,。
研究者分析了26篇科學(xué)家發(fā)表的關(guān)于II型糖尿病和淋巴瘤,、白血病關(guān)系的相關(guān)研究論文,，而后研究者又對(duì)時(shí)間范圍內(nèi)超過(guò)17000名II型糖尿病患者和血癌患者進(jìn)行整合分析。最后總結(jié)道,，II型糖尿病患者患白血病,、骨髓瘤以及非霍奇金淋巴瘤的風(fēng)險(xiǎn)明顯增加，更有意思的是,，研究者發(fā)現(xiàn)患淋巴瘤,、骨髓瘤以及白血病的患者會(huì)因地區(qū)不同，其發(fā)病風(fēng)險(xiǎn)也不盡相同,，比如,，非霍奇金淋巴瘤在亞洲和歐洲比較高發(fā)，而白血病在美國(guó)和亞洲比較高發(fā),。
研究并沒(méi)有發(fā)現(xiàn)為什么II型糖尿病為什么和這些疾病相關(guān),，研究者表示，他們后期還會(huì)進(jìn)行一些深入研究來(lái)解釋II型糖尿病和血癌之間的潛在關(guān)系,。Castillo后期會(huì)重點(diǎn)研究肥胖,、物理活動(dòng)、抽煙相關(guān)的行為因素,，這些都和糖尿病,、癌癥有一定的關(guān)系。相關(guān)研究由國(guó)立衛(wèi)生研究院提供資助,。（生物谷Bioon.com）
編譯自：Type 2 Diabetes Linked to Increased Blood Cancer Risk
編譯者：T.Shen
doi:10.1182/blood-2011-06-362830
PMC:
PMID:
Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
Jorge J. Castillo1, Nikhil Mull2, John L. Reagan1, Saed Nemr2, and Joanna Mitri3
Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 is associated with increased risk of developing lymphoma, leukemia, and myeloma. A literature search identified 26 studies (13 case-control and 13 cohort studies) evaluating such an association. Outcome was calculated as the odds ratio (OR) using a random effects model. Heterogeneity and publication bias were evaluated using the I2 index and the trim-and-fill analysis, respectively. Quality was assessed using the Newcastle-Ottawa scale. The OR for non-Hodgkin lymphoma was increased at 1.22 (95% confidence interval [CI], 1.07-1.39; P < .01) but the OR for Hodgkin lymphoma was not. There was an increased OR for peripheral T-cell lymphoma (OR = 2.42, 95% CI, 1.24-4.72; P = .009) but not for other non-Hodgkin lymphoma subtypes. The OR for leukemia was 1.22 (95% CI, 1.03-1.44; P = .02) and the OR for myeloma was 1.22 (95% CI, 0.98-1.53; P = .08). Although diabetes mellitus type 2 seems to increase the risk of developing lymphoma, leukemia, and myeloma, future studies should focus on evaluating other potential confounders such as obesity, dietary habits, physical activity, and/or antidiabetic therapy.
